Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237335 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
A Phase 2 study of Cystic Fibrosis, sponsored by ReCode Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT06237335 is a Phase 2 study of Cystic Fibrosis that is actively recruiting participants, run by ReCode Therapeutics. The registered enrollment target is 192 participants, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT06237335, a Phase 2 study of Cystic Fibrosis, is actively recruiting participants, sponsored by ReCode Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ivacaftor
- DRUG RCT2100
Study Locations (20)
Other
- Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve - Montpellier
- Hôpital Necker Enfants Malades - Paris
- UMC Utrecht - Utrecht
- New Zealand Clinical Research (Part 1 Only) - Auckland
- University Hospitals Birmingham - Birmingham
- Royal Papworth Hospital - Cambridge
- Leeds Teaching Hospitals - Leeds
California
- Stanford University - Palo Alto
- UCSD - San Diego
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona - Tucson
Colorado
- National Jewish Health - Denver
Georgia
- Emory University - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237335
The ClinicalTrials.gov registry entry for NCT06237335 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target. The listed sponsor is ReCode Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06237335 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06237335 about?
NCT06237335 is a clinical study titled "A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF". This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
What is the current status of trial NCT06237335?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2024-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06237335 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06237335?
The interventions under investigation include: Placebo (OTHER), Ivacaftor (DRUG), RCT2100 (DRUG).
Who is sponsoring clinical trial NCT06237335?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06237335 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.